Objectives: To identify perioperative risk factors for postoperative systemic inflammatory response syndrome (SIRS) and suggest possible modifications to reduce morbidity. Material and Methods: We prospectively analysed perioperative data such as history of pervious stone surgery, number and configuration of stones, presence of stent or nephrostomy, any previous positive urine culture, intraoperative renal pelvic urine and stone culture, aspiration of turbid urine on initial puncture, number of tracts required and clearance of stones, operative time and intraoperative hypotension and tachycardia of all patients who underwent percutaneous nephrolithotomy over a period of 15 months. Results: A total of 182 patients were included, average stone size was 2.8 cm, 36.2% had staghorn stones and 15.9% had an indwelling stent or nephrostomy. Despite sterile preoperative urine culture, renal pelvic urine culture (RPUC) was positive in 14.8% (27 patients) and stone culture was positive in 21.9% (40 patients). SIRS developed in 17.5% (32 patients) and septic shock in 1.09% (2 patients). On analysis younger age, positive RPUC and stone culture, longer operative time and intraoperative tachycardia correlated significantly with the development of SIRS. Conclusion: Intra-operative cultures are only therapy-guiding cultures during SIRS, as preoperative urine cultures seldom accurately depict bacteriological status of upper tracts and thus should be obtained in all patients.

Keywords:
SIRS, PCNL, Post PCNL SIRS, Post PCNL sepsis
1.
Eğilmez T, Gören MR: Fever and systemic inflammatory response syndrome seen after percutaneous nephrolithotomy: review of 1290 adult patients. J Clin Anal Med 2015;6:196-201.
2.
Chen L, Xu QQ, Li JX, Xiong LL, Wang XF, Huang XB: Systemic inflammatory response syndrome after percutaneous nephrolithotomy: an assessment of risk factors. Int J Urol 2008;15:1025-1028.
3.
Taylor E, Miller J, Chi T, Stoller ML: Complications associated with percutaneous nephrolithotomy. Transl Androl Urol 2012;1:223-228.
4.
Kreydin EI, Eisner BH: Risk factors for sepsis after percutaneous renal stone surgery. Nat Rev Urol 2013;10:598-605.
5.
Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM consensus conference committee. American college of chest physicians/society of critical care medicine. Chest 1992;101:1644-1655.
6.
O'Keeffe NK, Mortimer AJ, Sambrook PA, Rao PN: Severe sepsis following percutaneous or endoscopic procedures for urinary tract stones. Br J Urol 1993;72:277-283.
7.
Draga RO, Kok ET, Sorel MR, Bosch RJ, Lock TM: Percutaneous nephrolithotomy: factors associated with fever after the first postoperative day and systemic inflammatory response syndrome. J Endourol 2009;23:921-927.
8.
Gutierrez J, Smith A, Geavlete P, Shah H, Kural AR, de Sio M, et al: Urinary tract infections and post-operative fever in percutaneous nephrolithotomy. World J Urol 2013;31:1135-1140.
9.
Fernandez A, Foell K, Nott L, Denstedt JD, Razvi H: Percutaneous nephrolithotripsy in patients with urinary diversions: a case-control comparison of perioperative outcomes. J Endourol 2011;25:1615-1618.
10.
Gault MH, Longerich LL, Crane G, Cooper R, Dow D, Best L, et al: Bacteriology of urinary tract stones. J Urol 1995;153:1164-1170.
11.
Fowler JE Jr: Bacteriology of branched renal calculi and accompanying urinary tract infection. J Urol 1984;131:213-215.
12.
Dogan HS, Guliyev F, Cetinkaya YS, Sofikerim M, Ozden E, Sahin A: Importance of microbiological evaluation in management of infectious complications following percutaneous nephrolithotomy. Int Urol Nephrol 2007;39:737-742.
13.
Gonen M, Turan H, Ozturk B, Ozkardes H: Factors affecting fever following percutaneous nephrolithotomy: a prospective clinical study. J Endourol 2008;22:2135-2138.
14.
Mariappan P, Smith G, Bariol SV, Moussa SA, Tolley DA: Stone and pelvic urine culture and sensitivity are better than bladder urine as predictors of urosepsis following percutaneous nephrolithotomy: a prospective clinical study. J Urol 2005;173:1610-1614.
15.
Mariappan P, Loong CW: Midstream urine culture and sensitivity test is a poor predictor of infected urine proximal to the obstructing ureteral stone or infected stones: a prospective clinical study. J Urol 2004;171(6 pt 1):2142-2145.
16.
Margel D, Ehrlich Y, Brown N, Lask D, Livne PM, Lifshitz DA: Clinical implication of routine stone culture in percutaneous nephrolithotomy - a prospective study. Urology 2006;67:26-29.
17.
Rao PN, Dube DA, Weightman NC, Oppenheim BA, Morris J: Prediction of septicemia following endourological manipulation for stones in the upper urinary tract. J Urol 1991;146:955-960.
18.
McAleer IM, Kaplan GW, Bradley JS, Carroll SF, Griffith DP: Endotoxin content in renal calculi. J Urol 2003;169:1813-1814.
19.
Wang Y, Jiang F, Wang Y, Hou Y, Zhang H, Chen Q, et al: Post-percutaneous nephrolithotomy septic shock and severe hemorrhage: a study of risk factors. Urol Int 2012;88:307-310.
20.
Zhong W, Zeng G, Wu K, Li X, Chen W, Yang H: Does a smaller tract in percutaneous nephrolithotomy contribute to high renal pelvic pressure and postoperative fever? J Endourol 2008;22:2147-2151.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.